Regular readers of The Marijuana Times are probably familiar with the name Insys Therapeutics. The opioid maker came to prominence in the cannabis community initially because of their $500,000 donation to a group fighting a marijuana legalization ballot measure in Arizona in 2016 (the measure eventually went down in defeat). It soon became clear that Insys was fighting legalization because they had plans to release their own synthetic spray derived from cannabinoids.
About a year ago, Insys got approval from the Drug Enforcement Administration for their new synthetic THC drug – Syndros – to be placed on Schedule II of the federal Controlled Substances Act, alongside drugs like cocaine, fentanyl (which Insys makes) and morphine; drugs with a high potential for abuse, yet still used for medical purposes. Natural cannabis resides in Schedule I, meaning the U.S. Government pretends it has a high potential for abuse and no medical uses.
While all of this has been going on, Insys has been slammed by scandal, including fraud charges brought by the Attorney General of Arizona.
Now Insys’ manufacturing arm has applied for permission to be a bulk manufacturer of a controlled substance – that substance being THC – which will then be used in the making of synthetic medications (click the link if you would like to leave a comment about this application before 5-29-18).